Search

Summary Lithium-ion batteries (LIBs) are currently the fastest growing segment of the global battery market, and the preferred electrochemical energy storage system for portable applications. Magnetism is one of the forces that can be applied improve performance, since the application of magnetic fields influences electrochemical reactions through variation of electrolyte properties, mass transportation, electrode kinetics, and deposits morphology. This review provides a description of the magnetic forces present in electrochemical reactions and focuses on how those forces may be taken advantage of to influence the LIBs components (electrolyte, electrodes, and active materials), improving battery performance. The different ways that magnetic forces can interact with LIBs components are discussed, as well as their influence on the electrochemical behavior. The suitable control of these forces and interactions can lead to higher performance LIBs structures and to the development of innovative concepts., Graphical abstract, Highlights • A review on the use use of magnetic fields on lithium-ion batteries is presented • The application of magnetic fields influences the electrochemical reactions • This influence ranges from the mass transport dynamics to the charge-discharge behavior • The application of magnetic fields allows it to improve lithium-ion batteries performance, Electromagnetic field; Energy storage; Energy systems; Magnetic property

Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044-1051, 2016. © 2016 Wiley Periodicals, Inc.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for over 70 benign and malignant hematologic and immunological processes. Over the past several decades, significant technological and post-transplant supportive advances have been made, resulting in a decrease in early transplant mortality and continued growth in the population of allo-HSCT survivors. With the expansion in the number of long-term survivors, as well as of those considering a transplant, the focus of transplant medicine has been shifted significantly to include a more prominent role for the care of the 'long-term' survivor. These patients have survived the acute critical phase of transplantation and have potentially achieved remission from their primary disease, yet allo-HSCT patients do not return to pre-transplant health status. For survivors >2 years removed, the time of transplant all-cause mortality is four- to nine-fold higher than age-matched peers within the general population. These patients represent a distinct, high-risk population that must be monitored for long-term transplant complications, including chronic GvHD (cGvHD), multi-organ dysfunctions and secondary malignancies. This article will review in a non-exhaustive manner, the approach to long-term care of an allo-HSCT recipient.

Not available